Signal Second child death disclosed in China gene-editing trial within months

Summary

A report published on 2026-08-06 revealed that a 6-year-old boy died during a Duchenne muscular dystrophy gene-editing trial conducted by Shanghai-based biotech firm HuidaGene. The child was the trial's last participant and had received a higher dose than prior participants, after which he developed acute respiratory distress syndrome amid a severe immune reaction. The trial had no independent data safety monitoring board, meaning the dose-escalation decision that preceded the death was never reviewed by anyone outside the study's own investigators. This marks the second child death disclosed in a China-based investigator-led gene-editing trial within months, following a March 2026 death at Shanghai's Xinhua Hospital that CNN revealed on 2026-07-30. The recurrence has intensified international scrutiny of safety oversight and transparency in China's investigator-led clinical trials.